CA3118062A1 - Percutaneous urinary catheter - Google Patents
Percutaneous urinary catheter Download PDFInfo
- Publication number
- CA3118062A1 CA3118062A1 CA3118062A CA3118062A CA3118062A1 CA 3118062 A1 CA3118062 A1 CA 3118062A1 CA 3118062 A CA3118062 A CA 3118062A CA 3118062 A CA3118062 A CA 3118062A CA 3118062 A1 CA3118062 A1 CA 3118062A1
- Authority
- CA
- Canada
- Prior art keywords
- catheter
- retention portion
- bladder
- patient
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002485 urinary effect Effects 0.000 title claims description 42
- 230000014759 maintenance of location Effects 0.000 claims abstract description 451
- 210000003734 kidney Anatomy 0.000 claims abstract description 292
- 210000000244 kidney pelvis Anatomy 0.000 claims abstract description 199
- 210000001635 urinary tract Anatomy 0.000 claims abstract description 91
- 230000001681 protective effect Effects 0.000 claims abstract description 57
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 26
- 239000012530 fluid Substances 0.000 claims description 291
- 238000000034 method Methods 0.000 claims description 70
- 230000001939 inductive effect Effects 0.000 claims description 24
- 230000007423 decrease Effects 0.000 claims description 23
- 230000007704 transition Effects 0.000 claims description 12
- 230000003187 abdominal effect Effects 0.000 claims description 4
- 230000004323 axial length Effects 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 description 417
- 210000002700 urine Anatomy 0.000 description 211
- 210000000626 ureter Anatomy 0.000 description 151
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 88
- 210000001519 tissue Anatomy 0.000 description 66
- 229940109239 creatinine Drugs 0.000 description 44
- 239000000463 material Substances 0.000 description 41
- 210000003708 urethra Anatomy 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 35
- 230000001965 increasing effect Effects 0.000 description 33
- 210000005239 tubule Anatomy 0.000 description 33
- 238000009826 distribution Methods 0.000 description 30
- 238000011282 treatment Methods 0.000 description 28
- 238000003780 insertion Methods 0.000 description 27
- 230000037431 insertion Effects 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 241000282898 Sus scrofa Species 0.000 description 23
- 206010020565 Hyperaemia Diseases 0.000 description 22
- 238000005534 hematocrit Methods 0.000 description 22
- 210000000885 nephron Anatomy 0.000 description 22
- 230000009724 venous congestion Effects 0.000 description 22
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 21
- 229910052708 sodium Inorganic materials 0.000 description 21
- 239000011734 sodium Substances 0.000 description 21
- 210000005068 bladder tissue Anatomy 0.000 description 20
- 230000009467 reduction Effects 0.000 description 20
- 230000006378 damage Effects 0.000 description 19
- 238000001914 filtration Methods 0.000 description 17
- -1 polytetrafluoroethylene Polymers 0.000 description 17
- 239000011148 porous material Substances 0.000 description 17
- 210000005084 renal tissue Anatomy 0.000 description 17
- 210000001631 vena cava inferior Anatomy 0.000 description 17
- 208000009304 Acute Kidney Injury Diseases 0.000 description 16
- 208000033626 Renal failure acute Diseases 0.000 description 16
- 201000011040 acute kidney failure Diseases 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000004891 communication Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 210000001736 capillary Anatomy 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 208000020832 chronic kidney disease Diseases 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 230000003907 kidney function Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 229910001000 nickel titanium Inorganic materials 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 238000002637 fluid replacement therapy Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 229920001296 polysiloxane Polymers 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 102000013519 Lipocalin-2 Human genes 0.000 description 9
- 108010051335 Lipocalin-2 Proteins 0.000 description 9
- 101100258315 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-1 gene Proteins 0.000 description 9
- 229920000954 Polyglycolide Polymers 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000004276 hyalin Anatomy 0.000 description 9
- 230000002706 hydrostatic effect Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 8
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000005484 gravity Effects 0.000 description 8
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 8
- 239000004810 polytetrafluoroethylene Substances 0.000 description 8
- 239000012781 shape memory material Substances 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- 206010016803 Fluid overload Diseases 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000003484 anatomy Anatomy 0.000 description 7
- 210000002565 arteriole Anatomy 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- 239000004816 latex Substances 0.000 description 7
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 230000008855 peristalsis Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000003741 urothelium Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 201000000523 end stage renal failure Diseases 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000002572 peristaltic effect Effects 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010016807 Fluid retention Diseases 0.000 description 5
- 206010059484 Haemodilution Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- 239000004814 polyurethane Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010007556 Cardiac failure acute Diseases 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000009056 active transport Effects 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000000210 loop of henle Anatomy 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- 229960001802 phenylephrine Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 210000002796 renal vein Anatomy 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 3
- 229920001299 polypropylene fumarate Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 2
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000002665 bowman capsule Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000005086 glomerual capillary Anatomy 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000012273 nephrostomy Methods 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000010024 tubular injury Effects 0.000 description 2
- 208000037978 tubular injury Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- ZHVLGOLHHYJSBZ-QRPNPIFTSA-N (2s)-1-phenylpropan-2-amine;phosphoric acid Chemical compound OP(O)(O)=O.C[C@H](N)CC1=CC=CC=C1 ZHVLGOLHHYJSBZ-QRPNPIFTSA-N 0.000 description 1
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000013156 embolectomy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000008663 renal system process Effects 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 102220015480 rs28763880 Human genes 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000004148 unit process Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/008—Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M2027/004—Implant devices for drainage of body fluids from one part of the body to another with at least a part of the circuit outside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1082—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1085—Bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1089—Urethra
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- External Artificial Organs (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/206,207 | 2018-11-30 | ||
| US16/206,207 US11229771B2 (en) | 2015-07-20 | 2018-11-30 | Percutaneous ureteral catheter |
| PCT/IB2019/060255 WO2020110046A1 (en) | 2018-11-30 | 2019-11-27 | Percutaneous urinary catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3118062A1 true CA3118062A1 (en) | 2020-06-04 |
Family
ID=68808471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118062A Pending CA3118062A1 (en) | 2018-11-30 | 2019-11-27 | Percutaneous urinary catheter |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3886960A1 (ja) |
| JP (2) | JP7506072B2 (ja) |
| CN (1) | CN113329782B (ja) |
| AU (1) | AU2019389902A1 (ja) |
| BR (1) | BR112021010025A2 (ja) |
| CA (1) | CA3118062A1 (ja) |
| MX (1) | MX2021006301A (ja) |
| WO (1) | WO2020110046A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102036629B (zh) | 2008-05-01 | 2013-12-18 | 康沃特克科技公司 | 直肠排泄用具 |
| JP6941442B2 (ja) | 2013-08-01 | 2021-09-29 | コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ | 流体格納容器とバッグコネクタシステムとを備えた排泄物管理システム |
| GB201721956D0 (en) | 2017-12-27 | 2018-02-07 | Convatec Ltd | Female catheter locator tip |
| GB201721955D0 (en) | 2017-12-27 | 2018-02-07 | Convatec Ltd | Catheter wetting devices |
| WO2020251979A1 (en) | 2019-06-11 | 2020-12-17 | Convatec Technologies Inc. | Urine collection bags for use with catheter products, kits incorporating the same, and methods therefor |
| CN113384796A (zh) * | 2021-06-24 | 2021-09-14 | 温州医科大学附属第一医院 | 一种免球囊留置导尿管 |
| CN118356296B (zh) * | 2024-06-20 | 2024-08-30 | 四川省医学科学院·四川省人民医院 | 一种换向式腹腔介入的多点热灌注引流装置及其方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709465B2 (en) | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
| PL364702A1 (en) | 1999-07-02 | 2004-12-13 | Coloplast A/S | An access member and a system for catheterization of the urinary bladder through an artificial or a natural canal in a user, and a method of replacing such an access member |
| US8328877B2 (en) | 2002-03-19 | 2012-12-11 | Boston Scientific Scimed, Inc. | Stent retention element and related methods |
| EP1599240A4 (en) * | 2003-02-24 | 2007-06-06 | Plc Medical Systems Inc | CATHETER METHOD AND SYSTEM APPLICABLE IN CASE OF ACUTE RENAL FAILURE |
| DK1957130T3 (da) | 2005-12-09 | 2010-11-22 | Dsm Ip Assets Bv | Hydrofilt overtræk omfattende en polyelektrolyt |
| WO2007075545A2 (en) * | 2005-12-16 | 2007-07-05 | Xoft, Inc. | Active drainage system for use in defined natural or surgically created body cavities or lumina |
| AU2015204868B2 (en) * | 2014-01-07 | 2019-05-16 | Potrero Medical, Inc. | Systems, devices and methods for draining and analyzing bodily fluids |
| US10512713B2 (en) * | 2015-07-20 | 2019-12-24 | Strataca Systems Limited | Method of removing excess fluid from a patient with hemodilution |
| RU2720403C2 (ru) | 2015-07-20 | 2020-04-29 | Стратака Системз Лимитед, Мт | Мочеточниковый катетер и мочепузырный катетер и способы создания отрицательного давления для увеличения почечной перфузии |
| US10926062B2 (en) * | 2015-07-20 | 2021-02-23 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
| WO2017019974A1 (en) | 2015-07-29 | 2017-02-02 | Renastent Llc | Transformable ureteral stent |
| US20180117288A1 (en) | 2016-11-03 | 2018-05-03 | Merit Medical Systems, Inc. | Drainage catheter |
| SE1750414A1 (en) * | 2017-04-04 | 2018-04-10 | Madeleine Ramstedt | Indwelling urethral device |
-
2019
- 2019-11-27 MX MX2021006301A patent/MX2021006301A/es unknown
- 2019-11-27 CA CA3118062A patent/CA3118062A1/en active Pending
- 2019-11-27 CN CN201980089718.3A patent/CN113329782B/zh active Active
- 2019-11-27 AU AU2019389902A patent/AU2019389902A1/en active Pending
- 2019-11-27 WO PCT/IB2019/060255 patent/WO2020110046A1/en active Application Filing
- 2019-11-27 BR BR112021010025-3A patent/BR112021010025A2/pt unknown
- 2019-11-27 JP JP2021530129A patent/JP7506072B2/ja active Active
- 2019-11-27 EP EP19816920.3A patent/EP3886960A1/en active Pending
-
2022
- 2022-11-25 JP JP2022188135A patent/JP7506136B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019389902A1 (en) | 2021-05-27 |
| CN113329782A (zh) | 2021-08-31 |
| TW202034864A (zh) | 2020-10-01 |
| JP7506072B2 (ja) | 2024-06-25 |
| JP7506136B2 (ja) | 2024-06-25 |
| JP2022515320A (ja) | 2022-02-18 |
| EP3886960A1 (en) | 2021-10-06 |
| JP2023015395A (ja) | 2023-01-31 |
| WO2020110046A1 (en) | 2020-06-04 |
| MX2021006301A (es) | 2021-07-16 |
| BR112021010025A2 (pt) | 2021-08-17 |
| CN113329782B (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10799668B2 (en) | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function | |
| US11229771B2 (en) | Percutaneous ureteral catheter | |
| US20210170149A1 (en) | Systems, Kits and Methods for Inducing Negative Pressure to Increase Renal Function | |
| US20200330723A1 (en) | Ureteral and Bladder Catheters and Methods of Inducing Negative Pressure to Increase Renal Perfusion | |
| US11541205B2 (en) | Coated urinary catheter or ureteral stent and method | |
| US20200094017A1 (en) | "Coated and/or Impregnated Ureteral Catheter or Stent and Method" | |
| EP3615125A1 (en) | Systems, Kits and Methods for Inducing Negative Pressure to Increase Renal Function | |
| US12064567B2 (en) | Percutaneous urinary catheter | |
| JP7506136B2 (ja) | 経皮的尿カテーテル | |
| JP7478150B2 (ja) | 負圧を誘発し、腎機能を増加させるための尿管カテーテル、膀胱カテーテル、システム、キット、および方法 | |
| EP3672656A1 (en) | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion | |
| CA3073907A1 (en) | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion | |
| US20220184342A1 (en) | Coated Urinary Catheter or Ureteral Stent and Method | |
| TWI856041B (zh) | 用於患者的尿道的導管與系統 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231123 |
|
| EEER | Examination request |
Effective date: 20231123 |